Back to top

Image: Shutterstock

Marsh Sees 8.2% Health Cost Surge in 2027: Consulting Growth Ahead?

Read MoreHide Full Article

Key Takeaways

  • MRSH expects employer health costs to rise 8.2% in 2027, topping $20,000 per worker after a 7.3% 2026 rise.
  • Drug costs rose 9.7% at large employers as GLP-1 coverage fell to 41% in 2026 from 49% a year earlier.
  • MRSH's Health and Benefits revenue rose 5% y/y underlying to $578 million in Q3 2026.

Marsh & McLennan Companies, Inc. (MRSH - Free Report) released its 2026 survey of employer health plans, showing how companies are fighting rising medical costs without abandoning employee coverage. The study found average benefit costs reached $18,777 per worker for 2026, up 7.3%. Employers expect employer-sponsored benefit costs to rise another 8.2% in 2027, pushing spending above $20,000 per employee.

Marsh highlighted changes in prescription coverage, including employers scaling back access to expensive GLP-1 weight-loss drugs or requiring coaching programs. It also pointed to growing interest in plans that steer employees toward carefully selected healthcare providers. Simon Camaj, Marsh’s US Health and Benefits leader, warned that unchecked increases could squeeze hiring and pay budgets, making smarter benefit design increasingly necessary.

The findings show healthcare is becoming a harder, more unpredictable expense for employers and workers to absorb. Prescription drug costs climbed 9.7% among large companies, while GLP-1 coverage fell from 49% of large employers in 2025 to 41% in 2026.

Employees felt the strain too: monthly family contributions in common PPO plans increased from $709 to $753, adding $528 annually. With health coverage influencing recruitment and retention, employers must carefully balance savings against the risk of frustrating staff or weakening benefits they value.

Rising benefit costs create both opportunity and urgency for Marsh. Companies facing tighter budgets may seek its guidance on plan design, pharmacy spending and provider networks, potentially supporting consulting demand. Reflecting momentum in this business, Marsh's Health and Benefits revenues grew 5% on an underlying basis in the third quarter of 2026, reaching $578 million. The business generated $1.85 billion in revenues during the first nine months, with growth across all regions.

How Are Marsh’s Peers Placed?

Peers like Aon plc (AON - Free Report) and Willis Towers Watson Public Limited Company (WTW - Free Report) are also positioned to benefit as employers seek relief from escalating healthcare expenses.

Aon's Health Solutions revenues climbed 6% year over year to $992 million in third-quarter 2026, supported by new business and strong client retention. Meanwhile, WTW's Health business delivered 6% organic revenue growth, benefiting from new business and renewals across regions. WTW also cited sustained employer demand for assistance in designing and managing healthcare programs amid elevated costs. While these trends indicate a favorable consulting environment, growing competition could limit pricing power and impact gains.

MRSH’s Price Performance, Valuation and Estimates

Shares of Marsh have gained 11.1% year to date against the industry’s decline of 6.4%.

Zacks Investment Research Image Source: Zacks Investment Research

From a valuation standpoint, Marsh trades at a forward price-to-earnings ratio of 18.21X, higher than the industry average but below its five-year median. MRSH currently has a Value Score of C.

Zacks Investment Research Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Marsh’s 2026 earnings implies a 7.6% increase year over year.

Zacks Investment Research Image Source: Zacks Investment Research

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Published in